• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Senti Biosciences Inc. (Amendment)

    2/14/23 11:52:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SNTI alert in real time by email
    SC 13G/A 1 d405260dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    SENTI BIOSCIENCES INC

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    81726A100

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d–1(b)

     

    ☒

    Rule 13d–1(c)

     

    ☐

    Rule 13d–1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 81726A100

     

      (1)    

      Names of reporting persons

     

      Sculptor Capital LP

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☒

     

      (3)  

      SEC use only

     

      (4)  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       (5)    

      Sole voting power

     

      0

       (6)  

      Shared voting power

     

      0

       (7)  

      Sole dispositive power

     

      0

       (8)  

      Shared dispositive power

     

      0

      (9)    

      Aggregate amount beneficially owned by each reporting person

     

      0

    (10)  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

    (11)  

      Percent of class represented by amount in Row (9)

     

      0.00%

    (12)  

      Type of reporting person (see instructions)

     

      IA


    CUSIP No. 81726A100

     

      (1)    

      Names of reporting persons

     

      Sculptor Capital II LP

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☒

     

      (3)  

      SEC use only

     

      (4)  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       (5)    

      Sole voting power

     

      0

       (6)  

      Shared voting power

     

      0

       (7)  

      Sole dispositive power

     

      0

       (8)  

      Shared dispositive power

     

      0

      (9)    

      Aggregate amount beneficially owned by each reporting person

     

      0

    (10)  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

    (11)  

      Percent of class represented by amount in Row (9)

     

      0.00%

    (12)  

      Type of reporting person (see instructions)

     

      IA


    CUSIP No. 81726A100

     

      (1)    

      Names of reporting persons

     

      Sculptor Capital Holding Corp.

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☒

     

      (3)  

      SEC use only

     

      (4)  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       (5)    

      Sole voting power

     

      0

       (6)  

      Shared voting power

     

      0

       (7)  

      Sole dispositive power

     

      0

       (8)  

      Shared dispositive power

     

      0

      (9)    

      Aggregate amount beneficially owned by each reporting person

     

      0

    (10)  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

    (11)  

      Percent of class represented by amount in Row (9)

     

      0.00%

    (12)  

      Type of reporting person (see instructions)

     

      CO


    CUSIP No. 81726A100

     

      (1)    

      Names of reporting persons

     

      Sculptor Capital Holding II LLC

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☒

     

      (3)  

      SEC use only

     

      (4)  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       (5)    

      Sole voting power

     

      0

       (6)  

      Shared voting power

     

      0

       (7)  

      Sole dispositive power

     

      0

       (8)  

      Shared dispositive power

     

      0

      (9)    

      Aggregate amount beneficially owned by each reporting person

     

      0

    (10)  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

    (11)  

      Percent of class represented by amount in Row (9)

     

      0.00%

    (12)  

      Type of reporting person (see instructions)

     

      CO


    CUSIP No. 81726A100

     

      (1)    

      Names of reporting persons

     

      Sculptor Capital Management, Inc.

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☒

     

      (3)  

      SEC use only

     

      (4)  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       (5)    

      Sole voting power

     

      0

       (6)  

      Shared voting power

     

      0

       (7)  

      Sole dispositive power

     

      0

       (8)  

      Shared dispositive power

     

      0

      (9)    

      Aggregate amount beneficially owned by each reporting person

     

      0

    (10)  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

    (11)  

      Percent of class represented by amount in Row (9)

     

      0.00%

    (12)  

      Type of reporting person (see instructions)

     

      CO


    CUSIP No. 81726A100

     

      (1)    

      Names of reporting persons

     

      Sculptor Master Fund, Ltd.

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☒

     

      (3)  

      SEC use only

     

      (4)  

      Citizenship or place of organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       (5)    

      Sole voting power

     

       (6)  

      Shared voting power

     

      0

       (7)  

      Sole dispositive power

     

       (8)  

      Shared dispositive power

     

      0

      (9)    

      Aggregate amount beneficially owned by each reporting person

     

      0

    (10)  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

    (11)  

      Percent of class represented by amount in Row (9)

     

      0.00%

    (12)  

      Type of reporting person (see instructions)

     

      CO


    CUSIP No. 81726A100

     

      (1)    

      Names of reporting persons

     

       Sculptor Special Funding, LP

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☒

     

      (3)  

      SEC use only

     

      (4)  

      Citizenship or place of organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       (5)    

      Sole voting power

     

       (6)  

      Shared voting power

     

      0

       (7)  

      Sole dispositive power

     

       (8)  

      Shared dispositive power

     

      0

      (9)    

      Aggregate amount beneficially owned by each reporting person

     

      0

    (10)  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

    (11)  

      Percent of class represented by amount in Row (9)

     

      0.00%

    (12)  

      Type of reporting person (see instructions)

     

      CO


    CUSIP No. 81726A100

     

      (1)    

      Names of reporting persons

     

       Sculptor Credit Opportunities Master Fund, Ltd.

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☒

     

      (3)  

      SEC use only

     

      (4)  

      Citizenship or place of organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       (5)    

      Sole voting power

     

       (6)  

      Shared voting power

     

      0

       (7)  

      Sole dispositive power

     

       (8)  

      Shared dispositive power

     

      0

      (9)    

      Aggregate amount beneficially owned by each reporting person

     

      0

    (10)  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

    (11)  

      Percent of class represented by amount in Row (9)

     

      0.00%

    (12)  

      Type of reporting person (see instructions)

     

      CO


    CUSIP No. 81726A100

     

      (1)    

      Names of reporting persons

     

      Sculptor SC II LP

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☒

     

      (3)  

      SEC use only

     

      (4)  

      Citizenship or place of organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       (5)    

      Sole voting power

     

       (6)  

      Shared voting power

     

      0

       (7)  

      Sole dispositive power

     

       (8)  

      Shared dispositive power

     

      0

      (9)    

      Aggregate amount beneficially owned by each reporting person

     

      0

    (10)  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

    (11)  

      Percent of class represented by amount in Row (9)

     

      0.00%

    (12)  

      Type of reporting person (see instructions)

     

      CO


    CUSIP No. 81726A100

     

      (1)    

      Names of reporting persons

     

      Sculptor Enhanced Master Fund, Ltd.

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☒

     

      (3)  

      SEC use only

     

      (4)  

      Citizenship or place of organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       (5)    

      Sole voting power

     

       (6)  

      Shared voting power

     

      0

       (7)  

      Sole dispositive power

     

       (8)  

      Shared dispositive power

     

      0

      (9)    

      Aggregate amount beneficially owned by each reporting person

     

      0

    (10)  

      Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

    (11)  

      Percent of class represented by amount in Row (9)

     

      0.00%

    (12)  

      Type of reporting person (see instructions)

     

      CO


      •  

    Sculptor Capital LP (“Sculptor”), a Delaware limited partnership, is the principal investment manager to a number of private funds and discretionary accounts (collectively, the “Accounts”).

     

      •  

    Sculptor Capital II LP (“Sculptor-II”), a Delaware limited partnership that is wholly owned by Sculptor, also serves as the investment manager to certain of the Accounts. The Common Stock reported in this Schedule 13G are held in the Accounts managed by Sculptor and Sculptor-II.

     

      •  

    Sculptor Capital Holding Corporation (“SCHC”), a Delaware corporation, serves as the general partner of Sculptor.

     

      •  

    Sculptor Capital Holding II LLC (“SCHC-II”), a Delaware limited liability company that is wholly owned by Sculptor, serves as the general partner of Sculptor-II.

     

      •  

    Sculptor Capital Management, Inc. (“SCU”), a Delaware limited liability company, is a holding company that is the sole shareholder of SCHC and the ultimate parent company of Sculptor and Sculptor-II.

     

      •  

    Sculptor Master Fund, Ltd. (“SCMF”) is a Cayman Islands company. Sculptor is the investment adviser to SCMF.

     

      •  

    Sculptor Special Funding, LP (“NRMD”) is a Cayman Islands exempted limited partnership that is wholly owned by SCMF.

     

      •  

    Sculptor Credit Opportunities Master Fund, Ltd. (“SCCO”) is a Cayman Islands company. Sculptor is the investment adviser to SCCO.

     

      •  

    Sculptor SC II LP (“NJGC”) is a Delaware limited partnership. Sculptor-II is the investment adviser to NJGC.

     

      •  

    Sculptor Enhanced Master Fund, Ltd. (“SCEN”) is a Cayman Islands company. Sculptor is the investment adviser to SCEN.

     

      •  

    The address of the principal business offices of Sculptor, Sculptor-II, SCHC, SCHC-II, SCU, SCMF, NRMD, SCEN, SCCO and NJGC is 9 West 57 Street, 39 Floor, New York, NY 10019.

    Item 1(a) Name of issuer:

    SENTI BIOSCIENCES INC, a Delaware corporation (the “Issuer”)

    Item 1(b) Address of issuer’s principal executive offices:

    2 Corporate Drive, First Floor

    South San Francisco, CA 94080

    2(a) Name of person filing:

    Sculptor Capital LP

    2(b) Address or principal business office or, if none, residence:

    9 West 57th Street, New York, New York 10019

    2(c) Citizenship:

    Delaware

    2(d) Title of class of securities:

    Common Stock, par value $0.0001 per share

    2(e) CUSIP No.: 81726A100


    Item 3.

    If this statement is filed pursuant to §§240.13d–1(b) or 240.13d–2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a–8);
    (e)    ☐    An investment adviser in accordance with §240.13d–1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d–1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with §240.13d–1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a–3);
    (j)    ☐    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with §240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________________________________

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned: 0

    (b) Percent of class: 0.00%


    SCHEDULE 13G

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote 0.

    (ii) Shared power to vote or to direct the vote 0

    (iii) Sole power to dispose or to direct the disposition of 0

    (iv) Shared power to dispose or to direct the disposition of 0

    Sculptor and Sculptor-II serve as the principal investment managers to the Accounts and thus may be deemed beneficial owners of the Common Stock in the Accounts managed by Sculptor and Sculptor-II. SCHC-II serves as the sole general partner of Sculptor-II and is wholly owned by Sculptor. SCHC serves as the sole general partner of Sculptor. As such, SCHC and SCHC-II may be deemed to control Sculptor as well as Sculptor-II and, therefore, may be deemed to be the beneficial owners of the Common Stock reported in this Schedule 13G. SCU is the sole shareholder of SCHC, and, for purposes of this Schedule 13G, may be deemed a beneficial owner of the Common Stock reported herein.

    The percentages reported in this Schedule 13G have been calculated based on 43,857,077 shares of Common Stock, as set forth in the Issuer’s Form 10-Q filed November 14, 2022.

     

    Item 5.

    Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ☐.

    Dissolution of a group requires a response to this item.

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person.

    See Item 4.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    N/A

     

    Item 8.

    Identification and Classification of Members of the Group.

    See Item 4.

     

    Item 9.

    Notice of Dissolution of Group.

    N/A

     

    Item 10.

    Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under §240.14a-11.


    Signatures

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2023

       SCULPTOR CAPITAL LP
       By: Sculptor Capital Holding Corporation, its General Partner
       Signature: /s/ Wayne Cohen
       Name: Wayne Cohen
       Title: President and Chief Operating Officer
       SCULPTOR CAPITAL II LP
       By: Sculptor Capital Holding II LLC, its General Partner
       By: Sculptor Capital LP, its Member
       By: Sculptor Capital Holding Corporation, its General Partner
       Signature: /s/ Wayne Cohen
       Name: Wayne Cohen
       Title: President and Chief Operating Officer
       SCULPTOR CAPITAL HOLDING CORPORATION
       Signature: /s/ Wayne Cohen
       Name: Wayne Cohen
       Title: President and Chief Operating Officer
       SCULPTOR CAPITAL HOLDING II LLC
       Signature: /s/ Wayne Cohen
       Name: Wayne Cohen
       Title: President and Chief Operating Officer
       SCULPTOR CAPITAL MANAGEMENT, INC.
       Signature: /s/ Wayne Cohen
       Name: Wayne Cohen
       Title: President and Chief Operating Officer
       SCULPTOR MASTER FUND, LTD.
       By: Sculptor Capital LP, its investment manager
       By: Sculptor Capital Holding Corporation, its General Partner
       Signature: /s/ Wayne Cohen
       Name: Wayne Cohen
       Title: President and Chief Operating Officer
       SCULPTOR SPECIAL FUNDING, LP
      

    By: Sculptor Capital LP, its investment manager

    By: Sculptor Capital Holding Corporation, its General Partner

    Signature:/s/ Wayne Cohen

    Name: Wayne Cohen

    Title: President and Chief Operating Officer

       SCULPTOR ENHANCED MASTER FUND, LTD.
      

    By: Sculptor Capital LP, its Investment Manager

    By: Sculptor Capital Holding Corporation, its General Partner

    Signature:/s/ Wayne Cohen

    Name: Wayne Cohen

    Title: President and Chief Operating Officer

       SCULPTOR CREDIT OPPORTUNITIES MASTER FUND, LTD.
       By: Sculptor Capital LP, its Investment Manager
       By: Sculptor Capital Holding Corporation, its General Partner
       Signature: /s/ Wayne Cohen
       Name: Wayne Cohen
       Title: President and Chief Operating Officer
       SCULPTOR SC II LP
       By: Sculptor Capital II LP, its Investment Manager
       By: Sculptor Capital Holding II LLC, its General Partner
       By: Sculptor Capital LP, its Member
       By: Sculptor Capital Holding Corporation, its General Partner
       Signature: /s/ Wayne Cohen
       Name: Wayne Cohen
       Title: President and Chief Operating Officer
    Get the next $SNTI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNTI

    DatePrice TargetRatingAnalyst
    6/6/2025$5.00Buy
    Laidlaw
    10/7/2022$7.50Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SNTI
    SEC Filings

    View All

    SEC Form 10-Q filed by Senti Biosciences Inc.

    10-Q - Senti Biosciences, Inc. (0001854270) (Filer)

    8/7/25 8:09:33 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Senti Biosciences, Inc. (0001854270) (Filer)

    8/7/25 8:06:35 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Biosciences Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Senti Biosciences, Inc. (0001854270) (Filer)

    7/18/25 8:56:49 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

    SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date/Time: Tuesday, August 19, 2025 at 2:20 PM ET Presenter: Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder and Chief Executive OfficerRegistration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform commit

    8/14/25 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio Participates in Virtual Investor "What This Means" Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

    Access the "What This Means" segment here SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor "What This Means" segment. For the segment, Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, discussed the Company's recently announced recommended Phase 2 dose selection for its potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell t

    8/12/25 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

    SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the second quarter of 2025 and provided a summary of recent pipeline and corporate highlights. "Our team has continued to advance SENTI-202's clinical development. We have now completed dose finding and have confirmed the recommended Phase 2 dose (RP2D), which is an important step in our Phase 1 study. We are currently in the dose expansion phase, enrolling additional patients with relapsed/refractory AML

    8/7/25 8:05:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Senti Bio with a new price target

    Laidlaw initiated coverage of Senti Bio with a rating of Buy and set a new price target of $5.00

    6/6/25 8:36:59 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley initiated coverage on Senti Bio with a new price target

    Morgan Stanley initiated coverage of Senti Bio with a rating of Equal-Weight and set a new price target of $7.50

    10/7/22 7:14:34 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Baum Bryan Daniel

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    7/21/25 5:56:55 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Baum Bryan Daniel

    3 - Senti Biosciences, Inc. (0001854270) (Issuer)

    7/21/25 5:55:39 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Collins James J.

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    6/27/25 7:55:15 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Leadership Updates

    Live Leadership Updates

    View All

    Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

    Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology licensing, correlation from "bench to bedside" and back and execution of scientific strategy SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the appointment of James B. Trager, Ph.D. to its Scientific Advisor

    4/10/25 8:45:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Senti Biosciences Inc.

    SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)

    2/14/23 12:38:17 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Senti Biosciences Inc. (Amendment)

    SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)

    2/14/23 11:52:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SNTI
    Financials

    Live finance-specific insights

    View All

    Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

    SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date/Time: Tuesday, August 19, 2025 at 2:20 PM ET Presenter: Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder and Chief Executive OfficerRegistration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform commit

    8/14/25 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio Participates in Virtual Investor "What This Means" Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

    Access the "What This Means" segment here SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor "What This Means" segment. For the segment, Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, discussed the Company's recently announced recommended Phase 2 dose selection for its potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell t

    8/12/25 9:15:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025

    SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the second quarter of 2025 and provided a summary of recent pipeline and corporate highlights. "Our team has continued to advance SENTI-202's clinical development. We have now completed dose finding and have confirmed the recommended Phase 2 dose (RP2D), which is an important step in our Phase 1 study. We are currently in the dose expansion phase, enrolling additional patients with relapsed/refractory AML

    8/7/25 8:05:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care